

CONTACT

+972 50 5255158
 info@pbm-medical.com
 www.pbm-medical.com

VISION

To provide effective, affordable, and innovative home-based eye care treatments for patients suffering from retinal diseases.

PROBLEM

AMD – Age related Macular Degeneration is a chronic disease of aging. It is the leading cause of vision loss in adults over 65.

The first stage of the disease is called dry AMD, which has no medical treatment other than taking nutritional supplements called AREDS.


SOLUTION

SightRetain® - Phototherapy glasses based on PhotoBioModulation(PBM) technology for home-based treatment.

Our glasses can make a difference in the fight against AMD. Just wear them for a few minutes daily to help halt the development or improve the symptoms of this leading cause of blindness.

MARKET

The market size of AMD is estimated to be around 280 million people in 2023. This number is expected to grow to 340 million people by 2030. The majority of people with AMD live in the developed world with the United States, Europe, and Japan having the highest prevalence rates due to aging populations and risk factors such as smoking and obesity. The prevalence of AMD is estimated to be around 8% in people aged 65 and over.



COMPETITORS

A phototherapy device (CE approved) has recently been marketed for the treatment of AMD. However, this device is solely intended for use in eye clinics and hospital departments since its operation requires professional expertise. Treatment with this device therefore requires the patient to come to the clinic every second day.

COMPETITIVE ADVANTAGES

SightRetain® wearable glasses allows treatment at the patients' convenience in his home and only requires a few minutes of daily use. SightRetain® glasses are safe, affordable and easy to operate.

BUSINESS MODEL

We are evaluating few B2B business models.

Founder Team



Dr. OR SHMUELI
CMO



Prof. DAVID ENK
CTO



SHLOMO LEV
CEO